Related references
Note: Only part of the references are listed.An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
Ingeborg M. M. van Leeuwen et al.
CELL CYCLE (2012)
Mechanism-specific signatures for small-molecule p53 activators
Ingeborg M. M. van Leeuwen et al.
CELL CYCLE (2011)
Life and death of transcriptional co-activator p300
Jihong Chen et al.
EPIGENETICS (2011)
p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
M. Xia et al.
ONCOGENE (2011)
Induced pluripotent stem cells: opportunities and challenges
Keisuke Okita et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2011)
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53
C. F. Cheok et al.
CELL DEATH AND DIFFERENTIATION (2010)
An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner
Eun Loo Noh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Teruhisa Kawamura et al.
NATURE (2009)
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
Surojit Sur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds
Danwei Huangfu et al.
NATURE BIOTECHNOLOGY (2008)
Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells
David Ruau et al.
STEM CELLS (2008)
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination
Chit Fang Cheok et al.
MOLECULAR CANCER RESEARCH (2007)
Dangerous habits of a security guard: the two faces of p53 as a drug target
Andrei V. Gudkov et al.
HUMAN MOLECULAR GENETICS (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy
Dominique Kranz et al.
CANCER RESEARCH (2006)
Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A
M Gialitakis et al.
NUCLEIC ACIDS RESEARCH (2006)
Regulation of the INK4a/ARF locus by histone deacetylase inhibitors
A Matheu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor
P Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Pilot screening programme for small molecule activators of p53
RG Berkson et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis
K Peltonen et al.
PIGMENT CELL RESEARCH (2005)
Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors
D Carvajal et al.
CANCER RESEARCH (2005)
TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression
A Weber et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
The histone deacetylase inhibitor trichostatin A alters the pattern of DNA replication origin activity in human cells
MG Kemp et al.
NUCLEIC ACIDS RESEARCH (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells
H Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3
AL Gartel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin
R Furumai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor β-induced cell-cycle arrest
GF Claassen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
E Oda et al.
SCIENCE (2000)
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
HA Coller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
p300 collaborates with Sp1 and Sp3 in p21waf1/cip1 promoter activation induced by histone deacetylase inhibitor
HY Xiao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
